Article
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2014
Costa Carlota, Molina Miguel Angel, Drozdowskyj Ana, Giménez-Capitán Ana, Bertran-Alamillo Jordi, Karachaliou Niki, Gervais Radj, Massuti Bartomeu, Wei Jia, Moran Teresa, Majem Margarita, Felip Enriqueta, Carcereny Enric, Garcia-Campelo Rosario, Viteri Santiago, Taron Miquel, Ono Mayumi, Giannikopoulos Petros, Bivona Trever, Rosell Rafael
Abstract excerpt
PURPOSE: Concomitant genetic alterations could account for transient clinical responses to tyrosine kinase inhibitors of the EGF receptor (EGFR) in patients harboring activating EGFR mutations. EXPERIMENTAL DESIGN: We have evaluated the impact of pretreatment somatic EGFR T790M mutations, TP53 mutations, and Bcl-2 interacting mediator of cell death (BCL2L11, also known as BIM) mRNA expression in 95 patients with...
Topics
- Aged
- Aged, 80 and over
- Apoptosis Regulatory Proteins
- Bcl-2-Like Protein 11
- Carcinoma, Non-Small-Cell Lung
- Disease-Free Survival
- ErbB Receptors